Stop STALLING Act

Hozzl · 2024-03-13T15:50:21Z

Explore the details of Senate Bill 148 Stop STALLING Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/13/2024, 3:50 PM

Summary of Bill S 148

The Stop STALLING Act, also known as Bill 118 s 148, is a piece of legislation introduced in the US Congress with the aim of addressing delays in the approval process for infrastructure projects. The acronym STALLING stands for Streamlining Transportation Approvals, Limiting Litigation, and Expediting Necessary Reviews to Secure Infrastructure Long-Term Act.

The main goal of the Stop STALLING Act is to streamline the approval process for transportation projects by reducing unnecessary delays and expediting reviews. The bill aims to achieve this by setting deadlines for environmental reviews and permitting decisions, as well as limiting the ability of third parties to file lawsuits that could further delay projects.

Additionally, the Stop STALLING Act includes provisions to improve coordination between federal agencies involved in the approval process, as well as measures to increase transparency and accountability in decision-making. The bill also seeks to prioritize projects that have the greatest potential to improve transportation infrastructure and create jobs. Overall, the Stop STALLING Act is intended to address inefficiencies in the approval process for infrastructure projects and expedite the development of much-needed transportation improvements. The bill has garnered bipartisan support in Congress and is currently under consideration for passage.

Congressional Summary of S 148

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 148

Bill S 148 is currently in the status of Bill Introduced since January 30, 2023. Bill S 148 was introduced during Congress 118 and was introduced to the Senate on January 30, 2023. Bill S 148's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 21. as of March 1, 2023

Bipartisan Support of Bill S 148

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 148

Primary Policy Focus

Health

Potential Impact Areas

- Administrative remedies

- Business ethics

- Civil actions and liability

- Competition and antitrust

- Department of Health and Human Services

- Drug safety, medical device, and laboratory regulation

- Food and Drug Administration (FDA)

- Licensing and registrations

- Prescription drugs

- Public participation and lobbying

Alternate Title(s) of Bill S 148

Stop STALLING Act

A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

Stop STALLING Act

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act

Stop STALLING Act

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act